AbbVie’s immunology portfolio to offset Humira losses: GlobalData
Skyrizi (risankizumab) and Rinvoq (upadacitinib) are emerging as key replacements as sharp declines are expected for Humira
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Rinvoq
Crohn’s disease treatment market sees major shift with biosimilars and next-gen therapies:…
The recent launch of adalimumab biosimilars not only will cause an overall reduction in the cost of treatment, but also provide…
AbbVie’s Rinvoq for Crohn’s Disease to see rapid uptake by healthcare providers: GlobalData
It is expected that the prescribing patterns of Rinvoq by HCPs will follow an ongoing trend by gastroenterologists to be more…
Abbvie raises sales outlook of two new drugs to more than $17.5 billion in 2025
The company's previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion
US FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
The US Food and Drug Administration's boxed warnings on the labels of Rinvoq , Xeljanz and Olumiant flags the risk of…